Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 am PT. Gerrit Klaerner, Ph.D., will provide a business update and overview. A live webcast will be available on the Tricida website and archived for 30 days. Additionally, Tricida will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022, at 4:00 am PT, with a recording accessible for 90 days. The company focuses on developing veverimer, a treatment for chronic kidney disease (CKD) progression.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. The live presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 30 days following the presentation.

Tricida will also present at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be accessible on the Tricida website at IR.Tricida.com at 4:00 am PT / 7:00 am ET on Monday, January 10, 2022, and will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

 

FAQ

What is Tricida’s stock symbol?

Tricida's stock symbol is TCDA.

When will Tricida present at the J.P. Morgan Healthcare Conference?

Tricida will present at the J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 am PT.

What is the focus of Tricida's research?

Tricida focuses on developing veverimer, a drug designed to slow chronic kidney disease progression.

When will the H.C. Wainwright BIOCONNECT Conference presentation take place?

Tricida will present at the H.C. Wainwright BIOCONNECT Conference on January 10, 2022, at 4:00 am PT.

How long will the presentations be available for viewing?

The J.P. Morgan presentation will be archived for 30 days, while the H.C. Wainwright presentation will be available for 90 days.